Zohar Wilner-Habot - Publications

Adalimumab biosimilars compared to originator: impact on uveitic macular edema.

Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Published: April 02, 2026

Response to: 'Comment on 'Metagenomic next-generation sequencing: a game changer in the diagnosis of unique intraocular infections''.

Journal: Eye (London, England)

Published: February 25, 2026

Non-Neoplastic Disorders Mimicking Posterior Segment Inflammation.

Journal: Ocular immunology and inflammation

Published: October 17, 2025

Disease of the Year 2025: Uveitis Masquerade Syndromes Neoplastic Masquerades in Adults.

Journal: Ocular immunology and inflammation

Published: August 19, 2025

Adalimumab biosimilars have similar efficacy to originator adalimumab when treating non-infectious uveitis.

Journal: The British journal of ophthalmology

Published: April 23, 2025

OCULAR MANIFESTATIONS OF AUTOIMMUNE DISEASE

Journal: Harefuah

Published: March 26, 2025

SOLVING A MEDICAL MYSTERY THROUGH THE EYES OF A YOUNG PATIENT WITH MULTIPLE TATTOOS

Journal: Harefuah

Published: March 26, 2025

Metagenomic next-generation sequencing: a game-changer in the diagnosis of unique intraocular infections.

Journal: Eye (London, England)

Published: March 01, 2025

Evidence and Consensus Based Imaging Guidelines in Multiple Evanescent White Dot Syndrome Multimodal imaging in Uveitis (MUV) Taskforce Report 6.

Journal: American journal of ophthalmology

Published: February 28, 2025

Clinical Characterization and Prognostic Risk Factors of Susac Syndrome: A Retrospective Multicenter Study.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: December 18, 2024

Comparison of various treatment modalities in patients with primary vitreoretinal lymphoma: A systematic review and meta-analysis.

Journal: Clinical & experimental ophthalmology

Published: June 08, 2024

Reply.

Journal: Retina (Philadelphia, Pa.)

Published: April 02, 2024